Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020

Date: October 1, 2011
Pages: 28
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H9F1F66B8D9EN
Leaflet:

Download PDF Leaflet

Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020
Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020” provides Hycamtin sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2019). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Summary
  • Therapy area profile including patient population for the US and EU5
  • Analysis and review of Hycamtin including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Hycamtin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2006-2019 for Hycamtin in the US and EU5

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Cervical Cancer Market
2.2 Epidemiology
2.3 Etiology
  2.3.1 HPV Infections
  2.3.2 Lack of Regular Papanicolaou (pap) Tests
  2.3.3 Smoking
  2.3.4 Sexual History
  2.3.5 Birth Control Pills
2.4 GlobalData Pipeline Report Guidance

3 CERVICAL CANCER DISEASE: MARKET CHARACTERIZATION

3.1 Cervical Cancer Disease Market
3.2 Cervical Cancer Disease Market Forecasts and CAGR
3.3 Drivers and Barriers for the Cervical Cancer Market
  3.3.1 Life Threatening Disease
  3.3.2 Low Incidence
  3.3.3 High Use of off-labeled drugs
  3.3.4 Early Screening
  3.3.5 Emergence of Vaccines

4 TUMOR-NODE-METASTASES(TNM) CLASSIFICATION OF CERVICAL CANCER

5 HYCAMTIN

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
Randomized Phase III Trial of cisplatin with or without topotecan in Carcinoma of the Uterine Cervix
5.4 Approval History of Hycamtin
5.5 Factors Affecting Sales of Hycamtin
  5.5.1 Improved Efficacy
  5.5.2 Novel Mechanism of Action
  5.5.3 Generic Availability
  5.5.4 Low Competition
5.6 Drug Evaluation
Drug Risk Benefit Score
  5.6.1 Efficacy
  5.6.2 Safety
  5.6.3 Compliance
  5.6.4 Dosing Convenience
5.7 Intensity of Competition
5.8 Sales forecast
  5.8.1 Target patient Pool of Hycamtin
  5.8.2 Dosing
  5.8.3 Market Penetration
  5.8.4 Annual Cost of Therapy
  5.8.5 Sales Projections of Hycamtin

6 CERVICAL CANCER MARKET: APPENDIX

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
  6.3.8 Primary Research
  6.3.9 Expert Panels
6.4 Contact Us
6.5 Disclaimer
6.6 Sources

LIST OF TABLES

Table 1: Cervical Cancer, Estimated Incidences and Mortality, 2010–2020
Table 2: Cervical Cancer, US,EU-5 and Japan, Market Size Forecast ($bn), 2009–2020
Table 3: Results of GOG-0179 Trial
Table 4: Approvals of Hycamtin
Table 5: Drug Risk Benefit Score of Hycamtin
Table 6: Annual Cost of Therapy
Table 7: Cervical Cancer, Global, Estimated Sales of Hycamtin ($m) 2006-2019
Table 8: Cervical Cancer, The US, Estimated Sales of Hycamtin ($m) 2006- 2019
Table 9: Cervical Cancer, The UK, Estimated Sales of Hycamtin ($m) 2007-2019
Table 10: Cervical Cancer, France, Estimated Sales of Hycamtin ($m) 2007-2019
Table 11: Cervical Cancer, Germany, Estimated Sales of Hycamtin ($m) 2007-2019
Table 12: Cervical Cancer, Italy, Estimated Sales of Hycamtin ($m) 2007-2019
Table 13: Cervical Cancer, Spain, Estimated Sales of Hycamtin ($m) 2007- 2019

LIST OF FIGURES

Figure 1: Distribution by Incidence and Mortality, Top 26 Diagnosed Cancers
Figure 2: Difference Between Percentage Distribution of Incidence and Mortality of Top 20 Cancers, 2008
Figure 3: Per Capita Cigarette Consumption Curve, the US, 1976-2006
Figure 4: Cervical Cancer, US,EU-5 and Japan, Market Size Forecast ($bn), 2009–2020
Figure 5: Classification of Cervical Cancer
Figure 6: TNM Staging Classification
Figure 7: Classification of Cervical Cancer
Figure 8: Survival and PFS comparison of cisplatin with cisplatin plus topotecan
Figure 9 : Response rate comparison of cisplatin with cisplatin plus topotecan
Figure 10: Drug Model Diagram of Hycamtin
Figure 11: Cervical Cancer, Global, Estimated Sales of Hycamtin ($m) 2006-2019
Figure 12: Cervical Cancer, Global, Hycamtin Sales Distribution, 2019
Figure 13: Cervical Cancer, The US, Estimated Sales of Hycamtin ($m) 2006- 2019
Figure 14: Cervical Cancer, The UK, Estimated Sales of Hycamtin ($m) 2007- 2019
Figure 15: Cervical Cancer, France, Estimated Sales of Hycamtin ($m) 2007- 2019
Figure 16: Cervical Cancer, Germany, Estimated Sales of Hycamtin ($m) 2007- 2019
Figure 17: Cervical Cancer, Italy, Estimated Sales of Hycamtin ($m) 2007- 2019
Figure 18: Cervical Cancer, Spain, Estimated Sales of Hycamtin ($m) 2007- 2019
Figure 19: GlobalData Methodology
Figure 20: Drug Model Diagram
Figure 21: Patients Approved for the Drug

Ask Your Question

Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: